Program
Ingavirin Forte, 90 mg + 5 mg, Capsules
Also written as “Ingavirin Forte, 90 mg + 10 mg, Capsules” and “Ingavirin Forte, 90 mg + 20 mg, Capsules”.
Its studies are mostly in Influenza, Human, led by Valenta Pharm JSC.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Valenta Pharm JSC | 11 open or running | phase 2since Jan 15, 2026 | Jan 15, 2026 | Dec 31, 2027phase 2 · NCT07420985 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 15, 2026First study: phase 2 study in Influenza, HumanFirst studyNCT07420985 · 300 planned · Russia
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Influenza, HumanNCT07420985
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07420985Influenza, Human · Russia | 2 | Recruiting | Dec 31, 2027 | 300 |
How it is read
Names in the registry
- “Ingavirin Forte, 90 mg + 5 mg, Capsules”, 1 entry
- “Ingavirin Forte, 90 mg + 10 mg, Capsules”, 1 entry
- “Ingavirin Forte, 90 mg + 20 mg, Capsules”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.